Pulmatrix, Inc. (NASDAQ:PULM)

Pulmatrix, Inc. PULM

Healthcare - Biotechnology - NASDAQ - US

Watchlist

$ 6.56

39.6 %

$ 24 M

Market Cap

-2.2

P/E

1. INTRINSIC VALUE

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine.[ Read More ]

The intrinsic value of one PULM stock under the base case scenario is HIDDEN Compared to the current market price of 6.56 USD, Pulmatrix, Inc. is HIDDEN

PULM Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart PULM

FINANCIALS

Annual
Quarterly

7.3 M REVENUE

Growth Rates

1Year 20.21%

3Years -16.72%

5Years 116.62%

7Years 36.30%

10Years 27.30%

-14.7 M OPERATING INCOME

Growth Rates

1Year 22.20%

3Years -195.20%

5Years 6.23%

7Years 7.20%

10Years -39.64%

-14.1 M NET INCOME

Growth Rates

1Year 25.03%

3Years 9.90%

5Years 7.24%

7Years 9.24%

10Years -39.04%

-16 M OPERATING CASH FLOW

Growth Rates

1Year 17.42%

3Years -8.59%

5Years 0.94%

7Years -2.72%

10Years -43.69%

-676 K INVESTING CASH FLOW

Growth Rates

1Year -686.05%

3Years -33.99%

5Years -104.29%

7Years -6.64%

10Years -67.03%

53 K FINANCING CASH FLOW

Growth Rates

1Year -95.69%

3Years -86.38%

5Years -68.00%

7Years 10.80%

10Years -20.51%

366 K REVENUE

Growth Rates

1Year 20.21%

3Years -16.72%

5Years 116.62%

7Years 36.30%

10Years 27.30%

-2.66 M OPERATING INCOME

Growth Rates

1Year 22.20%

3Years -195.20%

5Years 6.23%

7Years 7.20%

10Years -39.64%

-2.59 M NET INCOME

Growth Rates

1Year 25.03%

3Years 9.90%

5Years 7.24%

7Years 9.24%

10Years -39.04%

-3.06 M OPERATING CASH FLOW

Growth Rates

1Year 17.42%

3Years -8.59%

5Years 0.94%

7Years -2.72%

10Years -43.69%

0 INVESTING CASH FLOW

Growth Rates

1Year -686.05%

3Years -33.99%

5Years -104.29%

7Years -6.64%

10Years -67.03%

0 FINANCING CASH FLOW

Growth Rates

1Year -95.69%

3Years -86.38%

5Years -68.00%

7Years 10.80%

10Years -20.51%

Balance Sheet Decomposition Pulmatrix, Inc.

34 M ASSETS
16 M LIABILITIES

Current Assets	20.8 M
Cash & Short-Term Investments	19.2 M
Receivables	928 K
Other Current Assets	742 K
Non-Current Assets	13.1 M
Long-Term Investments	0
PP&E	11.5 M
Other Non-Current Assets	1.65 M

Current Liabilities	3.91 M
Accounts Payable	1.92 M
Short-Term Debt	858 K
Other Current Liabilities	1.14 M
Non-Current Liabilities	12.1 M
Long-Term Debt	16.7 M
Other Non-Current Liabilities	-4.6 M

EFFICIENCY

Earnings Waterfall Pulmatrix, Inc.

Revenue	7.3 M
Cost Of Revenue	15.5 M
Gross Profit	-8.22 M
Operating Expenses	22 M
Operating Income	-14.7 M
Other Expenses	-619 K
Net Income	-14.1 M

RATIOS

-112.63% GROSS MARGIN

Averages

1Year -112.63%

3Years -78.55%

5Years -39.61%

7Years -1647.17%

10Years -1491.66%

-201.97% OPERATING MARGIN

Averages

1Year -201.97%

3Years -301.41%

5Years -234.07%

7Years -2810.71%

10Years -2545.53%

-193.49% NET MARGIN

Averages

1Year -193.49%

3Years -312.44%

5Years -284.16%

7Years -2892.93%

10Years -2664.96%

-78.47% ROE

Averages

1Year -78.47%

3Years -62.03%

5Years -98.88%

7Years -120.87%

10Years -126.55%

-41.58% ROA

Averages

1Year -41.58%

3Years -41.86%

5Years -51.35%

7Years -72.78%

10Years -75.49%

-55.10% ROIC

Averages

1Year -55.10%

3Years -53.09%

5Years -67.57%

7Years -91.49%

10Years -83.62%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Pulmatrix, Inc.

Net Income	-14.1 M
Depreciation & Amortization	1.48 M
Capital Expenditures	-676 K
Stock-Based Compensation	954 K
Change in Working Capital	-4.3 M
Others	-5.39 M
Free Cash Flow	-16.7 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Pulmatrix, Inc.

PULM has no price targets from Wall Street.

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

0 USD DIVIDEND PER SHARE

5. COMPETITION

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders.

-12.4 USD

CAPR

Overvalued 166.70%

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid.

0.786 USD

AKTX

Overvalued 62.23%

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.

10.3 USD

SLNO

Overvalued 80.19%

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States.

1.96 USD

BPTH

Undervalued 141.78%

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses.

11.6 USD

MBRX

Undervalued 329.15%

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States.

3.72 USD

BLPH

Undervalued 9962.22%

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors.

-5.18 USD

CRNX

Overvalued 109.46%

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States.

1.09 USD

ASMB

Overvalued 93.24%

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL).

-11.6 USD

TIL

Overvalued 143.72%

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer.

-0.0407 USD

CTMX

Overvalued 104.48%

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.

3.18 USD

ACHL

Undervalued 202.40%

6. Ownership

Insider Ownership Pulmatrix, Inc.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
6 years ago Apr 03, 2018	Bought 748 K USD	GILLIS STEVEN Director	+ 1150000	0.65 USD
6 years ago Apr 03, 2018	Bought 748 K USD	GILLIS STEVEN Director	+ 1150000	0.65 USD
6 years ago Apr 03, 2018	Bought 862 K USD	GILLIS STEVEN Director	+ 1150000	0.75 USD
6 years ago Apr 03, 2018	Bought 0 USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 769989	0 USD
6 years ago Apr 03, 2018	Bought 225 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 345551	0.65 USD
6 years ago Apr 03, 2018	Bought 577 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 769989	0.75 USD
6 years ago Apr 03, 2018	Bought 500 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 769989	0.65 USD
6 years ago Apr 03, 2018	Bought 225 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 345551	0.65 USD
6 years ago Apr 03, 2018	Bought 259 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 345551	0.75 USD
6 years ago Apr 03, 2018	Bought 0 USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 15007	0 USD
6 years ago Apr 03, 2018	Bought 0 USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 7700	0 USD
6 years ago Apr 03, 2018	Bought 0 USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 6478	0 USD
6 years ago Apr 03, 2018	Bought 0 USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 5275	0 USD
6 years ago Apr 03, 2018	Bought 9.75 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 15007	0.65 USD
6 years ago Apr 03, 2018	Bought 11.3 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 15007	0.75 USD
6 years ago Apr 03, 2018	Bought 5.78 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 7700	0.75 USD
6 years ago Apr 03, 2018	Bought 5 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 7700	0.65 USD
6 years ago Apr 03, 2018	Bought 4.21 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 6478	0.65 USD
6 years ago Apr 03, 2018	Bought 4.86 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 6478	0.75 USD
6 years ago Apr 03, 2018	Bought 3.43 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 5275	0.65 USD
6 years ago Apr 03, 2018	Bought 3.96 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 5275	0.75 USD
6 years ago Apr 03, 2018	Bought 200 K USD	Iwicki Mark T Director	+ 307000	0.65 USD
6 years ago Apr 03, 2018	Bought 200 K USD	Iwicki Mark T Director	+ 307000	0.65 USD
6 years ago Apr 03, 2018	Bought 230 K USD	Iwicki Mark T Director	+ 307000	0.75 USD
6 years ago Apr 03, 2018	Bought 13 K USD	Sherman Matthew L Director	+ 20000	0.65 USD
6 years ago Apr 03, 2018	Bought 13 K USD	Sherman Matthew L Director	+ 20000	0.65 USD
6 years ago Apr 03, 2018	Bought 15 K USD	Sherman Matthew L Director	+ 20000	0.75 USD
9 years ago Jun 15, 2015	Bought 491 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 71439	6.875 USD
9 years ago Jun 15, 2015	Bought 9.57 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 1392	6.875 USD
9 years ago Jun 15, 2015	Bought 4.92 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 715	6.875 USD
9 years ago Jun 15, 2015	Bought 3.37 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 490	6.875 USD
9 years ago Jun 16, 2015	Sell 2 M USD	Oculus Innovative Sciences, Inc. 10 percent owner	- 727500	2.75 USD
9 years ago Jun 17, 2015	Sell 2.54 M USD	Oculus Innovative Sciences, Inc. 10 percent owner	- 922500	2.75 USD
9 years ago Jun 15, 2015	Bought 491 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 71438	6.875 USD
9 years ago Jun 15, 2015	Bought 220 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 32059	6.875 USD
9 years ago Jun 15, 2015	Bought 9.57 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 1392	6.875 USD
9 years ago Jun 15, 2015	Bought 4.91 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 714	6.875 USD
9 years ago Jun 15, 2015	Bought 4.13 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 601	6.875 USD
9 years ago Jun 15, 2015	Bought 3.36 K USD	MCGUIRE TERRANCE director, 10 percent owner:	+ 489	6.875 USD
9 years ago Jun 16, 2015	Bought 500 K USD	GILLIS STEVEN Director	+ 72750	6.875 USD
9 years ago Jun 16, 2015	Bought 234 K USD	ROCKLAGE SCOTT M Director	+ 33990	6.875 USD
9 years ago Jun 16, 2015	Bought 33.1 K USD	ROCKLAGE SCOTT M Director	+ 4815	6.875 USD
9 years ago Jun 16, 2015	Bought 250 K USD	Maki David Director	+ 36375	6.875 USD
9 years ago Mar 23, 2015	Sell 962 K USD	Oculus Innovative Sciences, Inc. 10 percent owner	- 350000	2.75 USD

7. News

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders NEW YORK, NY / ACCESSWIRE / November 15, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Pulmatrix, Inc. (NASDAQ:PULM)'s merger with Cullgen Inc. Upon closing of the proposed transaction, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. If you are a Pulmatrix shareholder, click here to learn more about your rights and options. accesswire.com - 1 day ago

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pulmatrix, Inc. (NasdaqCM: PULM) and Cullgen Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whethe. businesswire.com - 2 days ago

PULM INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Pulmatrix, Inc. Merger WILMINGTON, DE / ACCESSWIRE / November 14, 2024 / Rigrodsky Law, P.A. is investigating Pulmatrix, Inc. ("Pulmatrix") (NASDAQ CM:PULM) regarding possible breaches of fiduciary duties and other violations of law related to Pulmatrix's agreement to merge with Cullgen Inc. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-pulmatrix-inc. accesswire.com - 2 days ago

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULM NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Pulmatrix , Inc. (NASDAQ: PULM ), relating to the proposed merger with Cullgen, Inc. Under the terms of the agreement, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. globenewswire.com - 2 days ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: globenewswire.com - 2 days ago

Shareholder Alert: Ademi LLP investigates whether Pulmatrix, Inc. is obtaining a Fair Price for its Public Shareholders MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Pulmatrix (Nasdaq: PULM) for possible breaches of fiduciary duty and other violations of law in its transaction with Cullgen. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company, and pre-merger Cullgen. businesswire.com - 3 days ago

PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Pulmatrix, Inc. (NASDAQ: PULM) and Cullgen Inc. is fair to Pulmatrix shareholders. Upon closing of the proposed transaction, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. Halper Sadeh encourages Pulmatrix shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or. businesswire.com - 3 days ago

Pulmatrix and Cullgen Announce Proposed Merger Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in or about to initiate Phase 1 clinical trials – two for the treatment of cancer and one for the treatment of acute and chronic pain Combined company expected to have approximately $65 million of cash and cash equivalents at close to provide funding through multiple clinical milestones and expected runway through 2026 As part of merger agreement, Pulmatrix intends to divest its assets including its acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE ™ technology Cullgen and Pulmatrix will host an informational webcast about the proposed merger that will be made available to access at 12:00 pm ET today FRAMINGHAM, Mass. and SAN DIEGO, Calif. prnewswire.com - 3 days ago

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update Closed transactions with MannKind Corporation validating the potential value of iSPERSE™ technology Pursuing strategic alternatives to further leverage iSPERSE ™ and optimize the potential of PUR3100 Completed PUR1900 wind down activities Cash runway projected into Q4 2026 FRAMINGHAM, Mass. , Nov. 8, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced third quarter financial results for 2024 and provided a corporate update on its clinical assets. prnewswire.com - 1 week ago

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update Completed series of transactions with MannKind Corporation validating iSPERSE ™ technology and extending projected cash runway into Q4 2026 $12.4 million in cash and cash equivalents at the end of Q2 2024, with an additional $1.4 million in restricted cash becoming unrestricted in August 2024 Pursuing strategic alternatives to further leverage iSPERSE ™ and optimize the potential of PUR3100 FRAMINGHAM, Mass. , Aug. 13, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced second quarter financial results for 2024 and provided a corporate update on its clinical assets. prnewswire.com - 3 months ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device. Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other related personal property in exchange for MannKind assumption of lease. prnewswire.com - 5 months ago

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) administered DHE. Self-administered PUR3100 showed improved safety and tolerability relative to IV DHE. prnewswire.com - 6 months ago

8. Profile Summary

Pulmatrix, Inc. PULM

COUNTRY US

INDUSTRY Biotechnology

MARKET CAP $ 24 M

Dividend Yield 0.00%

Description Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Contact 99 Hayden Avenue, Lexington, MA, 02421 https://www.pulmatrix.com

IPO Date March 21, 2014

Employees 22

Officers Dr. Alexander M. Klibanov Ph.D. Founder Mr. Peter Ludlum CMA, MBA Interim Chief Executive Officer

Price Chart PULM

Pulmatrix, Inc. PULM

Premium Plan

Unlimited Plan